九洲药业公告，2025年上半年营业收入28.71亿元，同比增长3.86%。净利润5.26亿元，同比增长 10.70%。公司2025年半年度利润分配预案为：以利润分配股权登记日总股本为基数，剔除回购专用账 户股份，向全体股东每10股派发现金股利2元（含税），不转增股本，不送红股。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603456 证券简称：九洲药业 公告编号：2025-045 浙江九洲药业股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、投资者可在2025年8月11日（星期一）下午15:00-16:00，通过互联网登录上证路演中心 （http://roadshow.sseinfo.com/），在线参与本次业绩说明会，公司将及时回答投资者的提问。 2、为提升交流效率，公司现提前向投资者征集相关问题，欢迎广大投资者于2025年8月4日（星期一） 至8月8日（星期五）16:00前登录上证路演中心网站首页，点击"提问预征集"栏目 （http://roadshow.sseinfo.com/questionCollection.do），根据活动时间，选中本次活动或通过公司邮箱 （603456@jiuzhoupharma.com）向公司提问，公司将在说明会上对投资者普遍关注的问题进行回答。 五、联系人及咨询办法 ● 会议 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-045 浙江九洲药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 8 月 11 日（星期一）15:00-16:00 二、说明会召开的时间、地点及方式 http://roadshow.sseinfo.com/） 三、公司参加人员 ? 会议召开方式：上证路演中心网络互动 ? 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ? 投资者可于 2025 年 8 月 4 日（星期一）至 8 月 8 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 一、说明会类型 浙江九洲药业股份有限公司（以下简称"公司"）将于 2025 年 8 月 6 日在上 ...

摘要显示，本发明涉及一种瑞博西尼中间体化合物及其制备方法，具有原辅料廉价，原子经济性高，绿 色安全，底物普适性高，工艺操作简单，适合工业化生产的优势，在此领域具有较大的潜力。 经济观察网天眼查APP显示，近日，浙江九洲药业（603456）股份有限公司、瑞博(苏州)制药有限公司 申请的"一种瑞博西尼中间体及其制备方法"专利公布。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇8月3日丨九洲药业(603456.SH)公告，浙江九洲药业股份有限公司(以下简称"公司")将于2025年8 月6日在上海证券交易所网站(www.sse.com.cn)披露公司2025年半年度报告。为便于广大投资者更全面、 深入地了解公司业绩和经营情况，公司计划于2025年8月11日(星期一)15:00-16:00召开2025年半年度业 绩说明会。公司将针对2025年半年度业绩、经营情况与投资者进行充分交流，在信息披露允许的范围内 就投资者普遍关注的公司经营业绩、战略规划、财务状况、利润分配等问题进行回答，欢迎广大投资者 积极参与。 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-045 浙江九洲药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 投资者可于 2025 年 8 月 4 日（星期一）至 8 月 8 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 一、说明会类型 浙江九洲药业股份有限公司（以下简称"公司"）将于 2025 年 8 月 6 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2025 年半年度报告。为便于广 大投资者更全面、深入地了解公司业绩和经营情况，公司计划于 2025 年 8 月 11 日（星期一）15:00-16:00 召开 2025 年半年度业绩说明会。公司将针对 2025 年 半年度业绩、经营情况与投资者进行充分交流，在信息披露允许的范围内就投资 者普遍关注的公司经营业绩、战略规划、财务状况、利润分配等问题进行回答， 欢迎广大投资者积极参与。 二、说明会召开的时间、地点及方式 1、会议召开时间： ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...

Core Viewpoint - The company has approved the use of idle raised funds for cash management, amounting to 785 million RMB, to enhance fund efficiency while ensuring the safety and liquidity of investments [1][7][12]. Summary by Sections Cash Management Overview - The cash management is aimed at improving fund efficiency and ensuring the safety of raised funds while not affecting the ongoing investment projects [2][12]. - The cash management products include bank certificates of deposit with a management period of 3, 6, and 12 months [1][7]. Cash Management Amount and Source - The total amount for cash management is 785 million RMB [4][7]. - The funds are sourced from idle raised funds from the company's non-public offerings in 2020 and 2022 [4][6]. Previous Cash Management Activities - The company previously used 21 million RMB of idle funds for cash management, which was redeemed with the principal and earnings returned to the special account for raised funds [2][5]. Approval Process - The cash management proposal was approved in the board meeting held on December 13, 2024, allowing the company to use up to 1.2 billion RMB for cash management under specific conditions [1][9]. Cash Management Product Details - The cash management products are required to be of high safety and liquidity, and the company ensures that these do not alter the intended use of raised funds [7][12]. - The income generated from cash management will belong to the company and will be returned to the special account upon maturity [8][12]. Impact on Company Operations - The use of idle raised funds for cash management will not affect the company's daily operations or the normal implementation of investment projects, aiming to enhance returns for shareholders [12].

Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced the establishment of special settlement accounts for cash management of idle raised funds, amounting to 785 million RMB, to enhance the efficiency of fund utilization and ensure the safety of the funds [1][9]. Group 1: Cash Management Overview - The cash management is entrusted to Industrial and Commercial Bank of China and Agricultural Bank of China [1]. - The cash management products include bank certificates of deposit with terms of 3 months, 6 months, and 12 months [1]. - The board of directors approved the use of up to 1.2 billion RMB of idle raised funds for cash management, ensuring it does not affect the construction and use of investment projects [1][9]. Group 2: Account Establishment - The company has opened sub-accounts for cash management at Agricultural Bank of China branches in Taizhou and Changshu [2]. - These accounts will be exclusively used for cash management of idle raised funds and will not be used for other purposes [4]. Group 3: Previous Cash Management Activities - Previously, the company used 21 million RMB of idle funds for cash management, which was redeemed by July 22, 2025, returning the principal and earnings to the special account [4]. Group 4: Purpose and Benefits of Cash Management - The purpose of cash management is to enhance fund efficiency while ensuring the safety of the raised funds and not impacting ongoing investment projects [5][10]. - The income generated from cash management will belong to the company and will be returned to the special account upon maturity [9]. Group 5: Regulatory Compliance - The cash management activities comply with relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [4][10]. - The company has received consent from its sponsor for the cash management activities [10].

Market Overview - The indices continued to rise collectively, with a significant drop in the morning followed by a recovery in sentiment in the afternoon [3] - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.33%, 0.64%, and 1.86% respectively, with over 3,000 stocks declining and more than 2,200 stocks rising [4] Optimizing Fertility - The "Implementation Plan for Childcare Subsidy System" was officially launched, providing annual subsidies of 3,600 yuan per child for children under three years old starting January 1, 2025 [8] - The fertility optimization sector saw a collective high opening but ended with a "high open low close" trend, with the sector rising by only 0.18% after an initial surge [9][10] - Stocks like Beiyinmei and Aiyingshi opened strongly but fell significantly, while stocks in the dairy sector also experienced a similar pattern [10] Yajiang Hydropower Station - The Yajiang Hydropower Station saw a rebound in the afternoon, with stocks like Xining Special Steel and Tibet Tianlu hitting the daily limit [15] - The Yajiang Hydropower concept stocks rose over 2% by the end of the day, indicating a recovery in investor interest [14] Stablecoin Sector - The stablecoin concept stocks experienced a partial rebound, with companies like Hengbao Co. and Sifang Jichuang showing strong performance [19] - The sector had been quiet for about two weeks but is now looking for a significant catalyst to revive interest [21] Guotou Intelligent - Guotou Intelligent saw a significant rise, closing up over 18.5%, attributed to news regarding a special action by the Internet Information Office [25] - The company is reportedly working on AI fraud prevention services, with a potential market space exceeding 120 billion yuan if it covers 1 billion smartphone users [28]